Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report

References

• TorreLABrayFSiegelRLFerlayJLieuleutJJemalAGlobal Cancer Statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• TianSQuanHXieCYN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivoCancer Sci201110271374138021443688
   PubMed Web of Science ®Google Scholar
• DingJChenXGaoZMetabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humansDrug Metab Dispos20134161195121023509226
   PubMed Web of Science ®Google Scholar
• LiJQinSXuJApatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trialJ Clin Oncol201331263219322523918952
   PubMed Web of Science ®Google Scholar
• LiJQinSXuJTrial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctionJ Clin Oncol20163413144826884585
   PubMed Web of Science ®Google Scholar
• LiJZhaoXChenLSafety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignanciesBMC Cancer20101052920923544
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, pen-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trialLancet Oncol20121323924622285168
   PubMed Web of Science ®Google Scholar
• WuYLZhouCLiamCKFirstline erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE studyAnn Oncol2015261883188926105600
   PubMed Web of Science ®Google Scholar
• MokTSWuYLAhnMJPlanchard D. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung CancerN Engl J Med201737662964027959700
   PubMed Web of Science ®Google Scholar
• ChatterjeeSHeukampLCSiobalMTumor VEGF: VEGFR2 autocrine feed forward loop triggers angiogenesis in lung cancerJ Clin Invest201312341732174023454747
   PubMed Web of Science ®Google Scholar
• LiHTakayamaKWangSAddition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expressionCancer Chemother Pharmacol20147461297130525344762
   PubMed Web of Science ®Google Scholar
• FolkmanJAngiogenesis in cancer, vascular, rheumatoid and other diseaseNat Med19951127317584949
   PubMed Web of Science ®Google Scholar
• EttingerDSWoodDEAkerleyWNCCN Guidelines Insight: non-small cell lung cancer, version 4. 2016J Natl Compr Canc Netw201614325526426957612
   PubMedGoogle Scholar
• GridelliCRossiACiardielloFBEVERLY: rationale and design of a randomized open-label phase III trial comparing bevacizumab plus erlotinib versus erlotinib alone as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small-cell lung cancerClin Lung Cancer201617546146527209164
   PubMed Web of Science ®Google Scholar
• ZhangSMaoXDWangHTCaiFXuJEfficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysisBMJ Open201666e011714
   PubMed Web of Science ®Google Scholar
• AriyasuRHoriikeAKoyamaJEfficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinibAnticancer Drugs2017
   PubMedGoogle Scholar
• SakataYKawamuraKShinquNIchikadoKErlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancerLung Cancer20169912012227565925
   PubMedGoogle Scholar
• PrandoniPCasigliaEPiccioliAThe risk of cancer in patients with venous thromboembolism does not exceed that expected in the general population after the first 6 monthsJ Thromb Haemost2010851126112720149076
   PubMedGoogle Scholar
• O’ConnellCHow I treat incidental pulmonary embolismBlood2015125121877188225533036
   PubMedGoogle Scholar
• KearonCAklEADuration of anticoagulant therapy for deep vein thrombosis and pulmonary embolismBlood2014123121794180124497538
   PubMed Web of Science ®Google Scholar
• LeeAYLevineMNBakerRILow-molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancerN Engl J Med2003349214615312853587
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCKakkarAKDabigatran versus warfarin in the treatment of acute venous thromboembolismN Engl J Med2009361242342235219966341
   PubMed Web of Science ®Google Scholar
• SchulmanSKakkarAKGoldhaberSZTreatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysisCirculation2014129776477224344086
   PubMed Web of Science ®Google Scholar
• DingJFChenXYGaoZWMetabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humansDrug Metab Dispos20134161195121023509226
   PubMed Web of Science ®Google Scholar
• ScaglioneFNew oral anticoagulants: comparative pharmacology with vitamin K antagonistsClin Pharmacokinet2013522698223292752
   PubMed Web of Science ®Google Scholar
• ShortNJConnorsJMNew oral anticoagulants and the cancer patientOncologist2014191829324319019
   PubMed Web of Science ®Google Scholar